Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab.

Literature DB >> 29255100

Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab.

Aditi Khandelwal¹, Julie K Wright¹, Katerina Pavenski¹, Linda R Taggart².

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 2017 PMID： 29255100 PMCID： PMC5738249 DOI： 10.1503/cmaj.170508

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

7 in total

Review 1. C4bp binding to porin mediates stable serum resistance of Neisseria gonorrhoeae.

Authors: S Ram; M Cullinane; A M Blom; S Gulati; D P McQuillen; R Boden; B G Monks; C O'Connell; C Elkins; M K Pangburn; B Dahlbäck; P A Rice
Journal: Int Immunopharmacol Date: 2001-03 Impact factor: 4.932

2. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.

Authors: Andrew H Limper; Kenneth S Knox; George A Sarosi; Neil M Ampel; John E Bennett; Antonino Catanzaro; Scott F Davies; William E Dismukes; Chadi A Hage; Kieren A Marr; Christopher H Mody; John R Perfect; David A Stevens
Journal: Am J Respir Crit Care Med Date: 2011-01-01 Impact factor: 21.405

3. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors: Carla S Coffin; Scott K Fung; Mang M Ma
Journal: Can J Gastroenterol Date: 2012-12 Impact factor: 3.522

4. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.

Authors: Haruhiko Ninomiya; Naoshi Obara; Shigeru Chiba; Kensuke Usuki; Kaichi Nishiwaki; Itaru Matsumura; Tsutomu Shichishima; Shinichiro Okamoto; Jun-Ichi Nishimura; Kazuma Ohyashiki; Shinji Nakao; Kiyoshi Ando; Yoshinobu Kanda; Tatsuya Kawaguchi; Hideki Nakakuma; Daisuke Harada; Hirozumi Akiyama; Taroh Kinoshita; Keiya Ozawa; Mitsuhiro Omine; Yuzuru Kanakura
Journal: Int J Hematol Date: 2016-07-27 Impact factor: 2.490

5. Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009-2011.

Authors: Anna Belkacem; Eric Caumes; Jocelyne Ouanich; Vincent Jarlier; Sophie Dellion; Benoit Cazenave; Régis Goursaud; Flore Lacassin; Jacques Breuil; Olivier Patey
Journal: Sex Transm Infect Date: 2013-08-06 Impact factor: 3.519

6. Disseminated gonococcal infection in women.

Authors: April T Bleich; Jeanne S Sheffield; George D Wendel; Amy Sigman; F Gary Cunningham
Journal: Obstet Gynecol Date: 2012-03 Impact factor: 7.661

7. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors: C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal: N Engl J Med Date: 2013-06-06 Impact factor: 91.245

7 in total

4 in total

Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab.

Review 1. C4bp binding to porin mediates stable serum resistance of Neisseria gonorrhoeae.

2. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.

3. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

4. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.

5. Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009-2011.

6. Disseminated gonococcal infection in women.

7. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

1. Unusual Neisseria species as a cause of infection in patients taking eculizumab.

2. Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series.

Review 3. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

4. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.